{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:26:46Z","timestamp":1782228406586,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Nobelpharma Co., Ltd"},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s13555-020-00387-7","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T06:02:41Z","timestamp":1588917761000},"page":"635-650","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Safety and Efficacy of the Sirolimus Gel for TSC Patients With Facial Skin Lesions in a Long-Term, Open-Label, Extension, Uncontrolled Clinical Trial"],"prefix":"10.1007","volume":"10","author":[{"given":"Mari","family":"Wataya-Kaneda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuuki","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Yokozeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Niizeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazue","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Ogai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Asahina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Fukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiharu","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izumi","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Takahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Shimasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Murota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,8]]},"reference":[{"issue":"4","key":"387_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","volume":"49","author":"DA Krueger","year":"2013","unstructured":"Krueger DA, Northrup H, International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):255\u201365.","journal-title":"Pediatr Neurol."},{"key":"387_CR2","unstructured":"Northrup H, Koenig MK, Pearson DA, Au KS. Tuberous sclerosis complex. GeneReviews(R), 1999 Jul 13 [Updated 2018 July 12]. Available at https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1220\/. Accessed May 2, 2019."},{"issue":"5","key":"387_CR3","doi-asserted-by":"publisher","first-page":"e63910","DOI":"10.1371\/journal.pone.0063910","volume":"8","author":"M Wataya-Kaneda","year":"2013","unstructured":"Wataya-Kaneda M, Tanaka M, Hamasaki T, Katayama I. Trends in the prevalence of tuberous sclerosis complex manifestations: an epidemiological study of 166 Japanese patients. PLoS ONE. 2013;8(5):e63910.","journal-title":"PLoS ONE"},{"issue":"2","key":"387_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jaad.2007.05.004","volume":"57","author":"RA Schwartz","year":"2007","unstructured":"Schwartz RA, Fern\u00e1ndez G, Kotulska K, J\u00f3\u017awiak S. Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol. 2007;57(2):189\u2013202.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"387_CR5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.1346-8138.1997.tb02758.x","volume":"24","author":"M Wataya-Kaneda","year":"1997","unstructured":"Wataya-Kaneda M, Yano K, Hosokawa K, Yoshikawa K. A case of tuberous sclerosis with a giant angiofibroma. J Dermatol. 1997;24(2):132\u20134.","journal-title":"J Dermatol"},{"issue":"1","key":"387_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1365-2133.1996.d01-923.x","volume":"135","author":"DW Webb","year":"1996","unstructured":"Webb DW, Clarke A, Fryer A, Osborne JP. The cutaneous features of tuberous sclerosis: a population study. Br J Dermatol. 1996;135(1):1\u20135.","journal-title":"Br J Dermatol"},{"issue":"10","key":"387_CR7","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1001\/jamadermatol.2014.938","volume":"150","author":"JM Teng","year":"2014","unstructured":"Teng JM, Cowen EW, Wataya-Kaneda M, et al. Dermatologic and dental aspects of the 2012 international tuberous sclerosis complex consensus statements. JAMA Dermatol. 2014;150(10):1095\u2013101.","journal-title":"JAMA Dermatol"},{"issue":"9861","key":"387_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","volume":"381","author":"DN Franz","year":"2013","unstructured":"Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381(9861):125\u201332.","journal-title":"Lancet"},{"issue":"9869","key":"387_CR9","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","volume":"381","author":"JJ Bissler","year":"2013","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9869):817\u201324.","journal-title":"Lancet"},{"issue":"10056","key":"387_CR10","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","volume":"388","author":"JA French","year":"2016","unstructured":"French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10056):2153\u201363.","journal-title":"Lancet"},{"issue":"17","key":"387_CR11","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","volume":"364","author":"FX McCormack","year":"2011","unstructured":"McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364(17):1595\u2013606.","journal-title":"N Engl J Med"},{"key":"387_CR12","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1001\/archdermatol.2011.254","volume":"147","author":"CM DeKlotz","year":"2011","unstructured":"DeKlotz CM, Ogram AE, Singh S, Dronavalli S, MacGregor JL. Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol. Arch Dermatol. 2011;147:1116\u20137.","journal-title":"Arch Dermatol."},{"issue":"7","key":"387_CR13","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/archdermatol.2010.125","volume":"146","author":"AK Haemel","year":"2010","unstructured":"Haemel AK, O\u2019Brian AL, Teng JM. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis. Arch Dermatol. 2010;146(7):715\u20138.","journal-title":"Arch Dermatol"},{"issue":"4","key":"387_CR14","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/j.1365-2133.2011.10471.x","volume":"165","author":"M Wataya-Kaneda","year":"2011","unstructured":"Wataya-Kaneda M, Tanaka M, Nakamura A, Matsumoto S, Katayama I. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity. Br J Dermatol. 2011;165(4):912\u20136.","journal-title":"Br J Dermatol"},{"issue":"7","key":"387_CR15","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jamadermatol.2018.1408","volume":"154","author":"M Wataya-Kaneda","year":"2018","unstructured":"Wataya-Kaneda M, Ohno Y, Fujita Y, et al. Sirolimus gel treatment vs placebo for facial angiofibromas in patients with tuberous sclerosis complex: a randomized clinical trial. JAMA Dermatol. 2018;154(7):781\u20138.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"387_CR16","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1111\/bjd.12567","volume":"169","author":"M Tanaka","year":"2013","unstructured":"Tanaka M, Wataya-Kaneda M, Nakamura A, Matsumoto S, Katayama I. First left-right comparative study of topical rapamycin vs vehicle for facial angiofibromas in patients with tuberous sclerosis complex. Br J Dermatol. 2013;169(6):1314\u20138.","journal-title":"Br J Dermatol"},{"issue":"1","key":"387_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/jamadermatol.2016.3545","volume":"153","author":"M Wataya-Kaneda","year":"2017","unstructured":"Wataya-Kaneda M, Nakamura A, Tanaka M, Hayashi M, Matsumoto S, Yamamoto K, Katayama I. Efficacy and safety of topical sirolimus therapy for facial angiofibromas in the tuberous sclerosis complex: a randomized clinical trial. JAMA Dermatol. 2017;153(1):39\u201348.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"387_CR18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","volume":"49","author":"H Northrup","year":"2013","unstructured":"Northrup H, Krueger DA, International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):243\u201354.","journal-title":"Pediatr Neurol."},{"issue":"3","key":"387_CR19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"387_CR20","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/j.1365-2133.1995.tb16953.x","volume":"132","author":"MS Lewis-Jones","year":"1995","unstructured":"Lewis-Jones MS, Finlay AY. The children\u2019s dermatology life quality index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942\u20139.","journal-title":"Br J Dermatol"},{"key":"387_CR21","unstructured":"Rapamune\u00ae (sirolimus) Label. https:\/\/labeling.pfizer.com\/showlabeling.aspx?id=139. Accessed May 2, 2019."},{"key":"387_CR22","unstructured":"Rapalimus\u00ae gel 0.2% Report on the deliberation results, PMDA 2018. https:\/\/www.pmda.go.jp\/files\/000225368.pdf. Accessed May 2, 2019."},{"issue":"2","key":"387_CR23","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1365-2133.2008.08677.x","volume":"159","author":"GF Hofbauer","year":"2008","unstructured":"Hofbauer GF, Marcollo-Pini A, Corsenca A, et al. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Br J Dermatol. 2008;159(2):473\u20135.","journal-title":"Br J Dermatol"},{"issue":"9","key":"387_CR24","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1016\/j.transproceed.2009.06.227","volume":"41","author":"A Tarasewicz","year":"2009","unstructured":"Tarasewicz A, Debska-Slizie\u0144 A, Konopa J, Zdrojewski Z, Rutkowski B. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex. Transplant Proc. 2009;41(9):3677\u201382.","journal-title":"Transplant Proc"},{"issue":"3","key":"387_CR25","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jdermsci.2019.05.002","volume":"94","author":"K Kitayama","year":"2019","unstructured":"Kitayama K, Maeda S, Nakamura A, Katayama I, Wataya-Kaneda M. Efficiency of sirolimus delivery to the skin is dependent on administration route and formulation. J Dermatol Sci. 2019;94(3):350\u20133.","journal-title":"J Dermatol Sci"},{"issue":"14","key":"387_CR26","doi-asserted-by":"publisher","first-page":"12509","DOI":"10.1074\/jbc.M110.200543","volume":"286","author":"H Ho","year":"2011","unstructured":"Ho H, Kapadia R, Al-Tahan S, Ahmad S, Ganesan AK. WIPI1 coordinates melanogenic gene transcription and melanosome formation via TORC1 inhibition. J Biol Chem. 2011;286(14):12509\u201323.","journal-title":"J Biol Chem"},{"issue":"7","key":"387_CR27","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jamadermatol.2014.4298","volume":"151","author":"M Wataya-Kaneda","year":"2015","unstructured":"Wataya-Kaneda M, Tanaka M, Yang L, et al. Clinical and histologic analysis of the efficacy of topical rapamycin therapy against hypomelanotic macules in tuberous sclerosis complex. JAMA Dermatol. 2015;151(7):722\u201330.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"387_CR28","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jid.2017.10.007","volume":"138","author":"F Yang","year":"2018","unstructured":"Yang F, Yang L, Wataya-Kaneda M, Yoshimura T, Tanemura A, Katayama I. Uncoupling of ER\/mitochondrial oxidative stress in mTORC1 hyperactivation-associated skin hypopigmentation. J Invest Dermatol. 2018;138(3):669\u201378.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"387_CR29","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jdermsci.2017.11.002","volume":"89","author":"F Yang","year":"2018","unstructured":"Yang F, Yang L, Wataya-Kaneda M, et al. Dysregulation of autophagy in melanocytes contributes to hypopigmented macules in tuberous sclerosis complex. J Dermatol Sci. 2018;89(2):155\u201364.","journal-title":"J Dermatol Sci"},{"issue":"7","key":"387_CR30","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1001\/jamadermatol.2018.0464","volume":"154","author":"MK Koenig","year":"2018","unstructured":"Koenig MK, Bell CS, Hebert AA, Treatment Trial Collaborators, et al. Efficacy and safety of topical rapamycin in patients with facial angiofibromas secondary to tuberous sclerosis complex: the TREATMENT randomized clinical trial. JAMA Dermatol. 2018;154(7):773\u201380.","journal-title":"JAMA Dermatol."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-020-00387-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-020-00387-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-020-00387-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T12:08:16Z","timestamp":1710504496000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-020-00387-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,8]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["387"],"URL":"https:\/\/doi.org\/10.1007\/s13555-020-00387-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,8]]},"assertion":[{"value":"30 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}